2020 Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

2020 Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

  • February 2020 •
  • 87 pages •
  • Report ID: 5863886 •
  • Format: PDF
The 2020 Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline report presents a comprehensive overview of the research and development of Cognitive Impairment Associated With Schizophrenia (CIAS) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Eight drugs in pre-clinical phase, five drugs in phase 1 and nine drugs in Phase 2

As of February 2020, the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline remains robust with 22 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Cognitive Impairment Associated With Schizophrenia (CIAS) treatment. Diverse types of targeted therapies are being explored through clinical trials including alpha 7 nicotinic acetylcholine receptor agonist; AMPA receptor modulators; D amino acid oxidase inhibitor; Dopamine D1 receptor positive allosteric modulator; estrogen receptor beta agonist; GABA A alpha 5 receptor modulators; glycine transporter 1 inhibitor; GPR139 agonist; Histamine H3 Inverse Agonist; Kv3 voltage-gated potassium channel; metabotropic glutamate receptor 5 (mGluR5); Muscarinic acetylcholine M4 receptor; NMDA receptor agonist; prolyl oligopeptidase inhibitor; Serotonin 4 receptor agonists.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Cognitive Impairment Associated With Schizophrenia (CIAS) drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

Publisher Expertise
Our online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

Scope:
• The report scope comprises of both pre-clinical phase and clinical phase development drugs for Cognitive Impairment Associated With Schizophrenia (CIAS) development
• Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline compounds and molecules under study by both large scale and small companies are included in the report
• Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
• Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
• Further, orphan drug status, fast track designation, different grants awarded and special status for Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline candidates included
• Business overview and snapshot of all companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline are included
• Latest market and pipeline developments are provided in the report

Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline companies included in the report are- Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, Autifony Therapeutics Ltd, Biogen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Cadent Therapeutics Inc, Chugai Pharmaceutical Co Ltd, Eli Lilly and Co, INVENT Pharmaceuticals Inc, Iproteos SL, Pfizer Inc, SK Biopharmaceuticals Co Ltd, Spherium Biomed SL, Suven Life Sciences Ltd, Takeda Pharmaceutical Co Ltd, Vanda Pharmaceuticals Inc

Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline drugs profiled in the report include- AVL-3288, ASP4345, ASP5736, VU-0467154, AUT 00206, BIIB104, BI 425809, BMS-955829, CAD-8688, erteberel, LSN2814617, basmisanil, Cognition disorder therapeutics, IPR-19, PF-03463275, SKL20540, SP-14040, SUVN-D4010, SUVN-G3031, TAK-041, TAK-831, VQW-765